Loading
A phase 3 trial of Fianlimab, Cemiplimab, Pembrolizumab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery is a phase 3 interventional study registered as NCT05608291 by Regeneron Pharmaceuticals, with 1564 participants enrolled, started 2023-01-16 and due to reach its primary completion in 2026-07-27. Interventions recorded: Fianlimab, Cemiplimab, Pembrolizumab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/